Navigation Links
Regeneron's Rilonacept Granted European Marketing Authorization for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
Date:10/27/2009

The most commonly reported adverse reactions with rilonacept were injection-site reaction and upper respiratory tract infection.

In the United States, rilonacept (ARCALYST®) is indicated for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS) in adults and children 12 and older. ARCALYST was approved by the U.S. Food and Drug Administration in February 2008 and has been available in the United States since March 2008.

IL-1 blockade may interfere with immune response to infections. Serious, life-threatening infections have been reported in patients taking rilonacept. Rilonacept should be discontinued if a patient develops a serious infection. Treatment with rilonacept should not be initiated in patients with active or chronic infections. Taking rilonacept with tumor necrosis factor inhibitors is not recommended because this may increase the risk of serious infections. Patients should not receive a live vaccine while taking rilonacept. It is recommended that patients receive all recommended vaccinations prior to initiation of treatment with rilonacept. Patients should be monitored for changes in their lipid profiles and provided with medical treatment if warranted. Hypersensitivity reactions associated with rilonacept administration have been rare. Please see the full U.S. Prescribing Information for ARCALYST® (rilonacept), available online at www.regeneron.com/ARCALYST-fpi.pdf. Please see the European Summary of Product Characteristics at www.regeneron.com/RILONACEPT-EU.pdf.

About Regeneron Pharmaceuticals

Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Celsis IVT Granted U.S. Patent for LiverPool(TM) Hepatocytes
2. Peripheral Artery Disease (PAD) Patent Granted to Dimera
3. Sundia and 2 Other CRO Companies Granted Express Customs Clearance Privilege in Shanghai
4. Delcath Systems Granted Third Orphan Drug Designation
5. Fate Therapeutics Granted Exclusive License for Stem Cell Modulators by Childrens Hospital Boston and Massachusetts General Hospital
6. FDA has Granted HUD (Humanitarian Use Device) Designation to ITGIs Pericardium Covered Stents, Over and Under(R) and Aneugraft(R), for Treatment of Perforations and Dissections of Native Coronary Arteries and Saphenous Vein Grafts
7. Clarient Granted Exclusive License to Commercialize Breast Cancer Biomarker by Indiana University Research and Technology Corporation
8. Tolera Therapeutics Granted Orphan Drug Designation for Organ Transplant Rejection Drug
9. VIASPACE Granted US Patent
10. Crisis Exemption Granted to Market Avipel(R) Corn Seed Treatment in Louisiana
11. Valdoxan(R) Granted Marketing Authorisation for the Treatment of Major Depressive Episodes in Europe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Willow Grove, PA (PRWEB) August 28, 2014 ... talent, and create a culture that will allow individuals ... that are becoming increasingly important for employers looking to ... life science industries are embracing this trend, as the ... the fabric of a company, which will have real ...
(Date:8/28/2014)... 2014   SunTrust Robinson Humphrey (STRH) ... to its equity research team in biotechnology and ... in equity research demonstrates our commitment to providing ... enhance their investment decision making," said Biff ... continue to make significant investments in differentiated content ...
(Date:8/28/2014)... Calif. , Aug. 28, 2014  Armetheon, ... on developing novel mid- to late-stage cardiovascular drug ... million in its first round of financing. The ... Investments and Hercules Bioventures with participation from investors ... and pharmaceutical executive, Dr. Larry Hsu , ...
(Date:8/28/2014)... Washington, USA (PRWEB) August 27, 2014 ... next month for SPIE Laser Damage 2014 ... optical materials for high-power lasers will run 14-17 September. ... society for optics and photonics . , The premier ... for understanding laser damage to optical materials will engage ...
Breaking Biology Technology:Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 3SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 3Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 2Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 3
... , NEW YORK, Sept. 9 ... Vice President and General Manager of Informatics at Thermo Fisher ... HUNT Research Center and Biobank, about data integration: the benefits ... life sciences companies. , , ...
... Mass., Sept. 9 EnVivo Pharmaceuticals today announced the appointment ... financial officer. DiPalma is responsible for overall financial operations ... , "EnVivo has grown to the point where ... our broad pipeline and increasing business opportunities," said Kees Been, ...
... , , PRINCETON, N.J., Sept. 9 ... clinical development services to innovative pharmaceutical, biotechnology, generic drug ... completely paid down its Convertible Senior Notes that were ... be used for general corporate purposes. , ...
Cached Biology Technology:Don't Wait to Innovate: Future Pharmaceuticals Magazine Releases Its Issue on Innovation in IT, Cell-Based Therapy and Supply Chains 2EnVivo Pharmaceuticals Names Stephen DiPalma Chief Financial Officer 2PharmaNet Development Group Provides Financial Update and Announces Geographic Expansion 2
(Date:8/29/2014)... the University of Texas Medical Branch at Galveston has gone ... can completely protect monkeys against a lethal dose of Ebola ... when the disease is severe. , Thomas Geisbert, professor of ... discussing advances in Ebola treatment research. The filoviruses known ... deadly of pathogens, with fatality rates of up to 90 ...
(Date:8/29/2014)... release is available in German . ... players in the natural nitrogen cycle on Earth and ... bacteria were thought to depend on nitrite as their ... by Holger Daims, a microbiologist at the University of ... hydrogen as an alternative source of energy. The oxidation ...
(Date:8/29/2014)... a cell,s nucleus, chromosomal DNA is tightly bound ... biologists call chromatin. Until about two decades ago, ... mere packing material around which the glamorous DNA ... a greater appreciation for how DNA/histone interactions govern ... research institutions studying the sequence of the genome ...
Breaking Biology News(10 mins):Leading Ebola researcher at UTMB says there's an effective treatment for Ebola 2Hydrogen powers important nitrogen-transforming bacteria 2Hydrogen powers important nitrogen-transforming bacteria 3'K-to-M' histone mutations: How repressing the repressors may drive tissue-specific cancers 2'K-to-M' histone mutations: How repressing the repressors may drive tissue-specific cancers 3
... come in various shapes and sizes. Each cell is shaped ... specific function. When things go wrong and a cell does ... and the cell can cause problems in the body. Researchers ... for Atomic and Molecular Physics (AMOLF), The Netherlands, have now ...
... scientists were able to differentiate metastatic cancer cells from ... measures the softness of the cells. The study, ... of the journal Nature Nanotechnology, represents one of the ... cells from cancer patients and apply nanotechnology to analyze ...
... from a key molecular receptor that normally switches on ... in the presence of stress and toxins may help ... in premature newborns, according to scientists at the American ... J. Hackam and his laboratory team at the Childrens ...
Cached Biology News:How cells keep in shape 2Using nanotechnology, UCLA researchers discover cancer cells 'feel' much softer than normal cells 2Using nanotechnology, UCLA researchers discover cancer cells 'feel' much softer than normal cells 3Using nanotechnology, UCLA researchers discover cancer cells 'feel' much softer than normal cells 4Leading cause of death in 'preemies' might be controlled by resetting a molecular switch 2